Cingulate Inc. (CING)
| Previous Close | 0.8800 |
| Open | 0.8466 |
| Bid | 0.8075 x 100 |
| Ask | 0.9439 x 100 |
| Day's Range | 0.8466 - 0.8999 |
| 52 Week Range | 0.7500 - 23.8000 |
| Volume | |
| Avg. Volume | 319,498 |
| Market Cap | 5.121M |
| Beta (5Y Monthly) | -0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -26.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.50 |
GlobeNewswireCingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 conference on Wednesday, May 1, 2024, at 2:30 PM PST. Management will also host individual investor meetings on Thursday, May 2. Meetings
- GlobeNewswire
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
$17.8 Million Raised Since Beginning of 2023$9.1 Million of Debt Converted to Equity at a PremiumPhase 3 ADHD Data Continues to Impress KANSAS CITY, Kan., April 01, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023
- GlobeNewswire
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday March 22, 2024, at 12 p.m. ET. The discussion will focus on Cingulate’s pipeline and product portfol
